Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2023-04-21 Remuneration Information
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA - Share Option Program
Remuneration Information Classification · 99% confidence The document explicitly details the resolution by the Board of Directors to issue share options to employees following approval at the General Meeting. It specifies the number of options (160,000), the vesting schedule, the exercise price (NOK 128.61), and notes a grant to a primary insider (CEO Carlos de Sousa). This content directly relates to changes in the company's capital structure concerning employee incentives, which aligns best with the 'Capital/Financing Update' category, as it involves the issuance of potential new shares as part of an incentive program. While it touches on insider dealings (CEO grant), the primary focus is the establishment and execution of the option program itself, making CAP the most appropriate fit over DIRS or SHA, which are broader.
2023-04-21 English
Ultimovacs ASA - Annual General Meeting held on 20 April 2023
AGM Information Classification · 100% confidence The document text is explicitly titled 'MINUTES OF THE ANNUAL GENERAL MEETING IN ULTIMOVACS ASA' (PROTOKOLL FRA ORDINÆR GENERALFORSAMLING I ULTIMOVACS ASA). The content details the proceedings, resolutions passed (including approval of annual accounts, remuneration, election of the board, and authorizations for capital changes), which are the defining characteristics of minutes from a General Meeting. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although it contains elements related to the Annual Report (item 3) and Remuneration (item 5), the document's primary function and title identify it as the official record of the meeting itself.
2023-04-20 Norwegian
Ultimovacs ASA - Annual General Meeting held on 20 April 2023
AGM Information Classification · 99% confidence The document explicitly states it concerns the 'Annual General Meeting held on 20 April 2023' for Ultimovacs ASA. It details the outcomes, specifically that all matters on the agenda were approved, including the re-election of all board members and the composition of the Nomination Committee. This content directly relates to the proceedings and outcomes of an AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short, but it contains the substance of the meeting's results, not just an announcement that minutes are available, making AGM-R more specific than RPA or RNS.
2023-04-20 English
Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly mentions 'Disclosure of voting rights of Annual General Meeting' and details the total voting rights and proxies received by the Chair of the Board in connection with the upcoming AGM on April 20, 2023. This content directly relates to the official results or pre-meeting status of shareholder votes, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). Although it is a pre-meeting disclosure, it concerns the voting outcome/status, making DVA more specific than a general Regulatory Filing (RNS) or AGM Information (AGM-R), which usually refers to the meeting materials themselves.
2023-04-14 English
Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations
Regulatory Filings Classification · 100% confidence The document is a press release from Ultimovacs ASA dated April 13, 2023, announcing that it received a 'Notice of Intention to Grant' from the European Patent Office regarding its UV1 cancer vaccine combinations. This announcement concerns intellectual property (patent rights) and is a specific corporate update. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A). Since it is a specific announcement about intellectual property/legal status that doesn't fit perfectly into the financial reporting categories, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific corporate news that isn't covered by the other specialized codes. Given the content is a specific corporate action/update, RNS is the most appropriate general regulatory filing code.
2023-04-13 English
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
AGM Information Classification · 98% confidence The document text consists of the Articles of Association ('Vedtekter'/'Articles of Association') for Ultimovacs ASA, detailing company structure, share capital, board composition, and procedures for the General Meeting. While it mentions the 'Annual General Meeting' (AGM) and the 'annual accounts and annual report' (which are typically approved at the AGM), the document itself is the foundational corporate charter, not a specific periodic filing like a 10-K, ER, or IR. Since there is no specific category for Articles of Association, and it is a formal corporate governance document, it is best classified under Governance Information (CGR), which covers internal rules and board structure, or potentially as a Regulatory Filing (RNS) if CGR is deemed too specific for foundational documents. Given the detailed structure regarding the Board, Nomination Committee, and General Meeting procedures, CGR is the most appropriate fit among the provided options, as it relates directly to corporate governance rules.
2023-03-24 Norwegian

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.